May 12, 2015 -
PRLog -- Immunotherapeutic approaches to cancer treatment continue to generate great interest. In an excellent Nature Reviews Cancer "Perspectives"
discussion, Coulie et.al. (2014) construct a timeline of seminal discoveries that established the framework for our present understanding of tumor rejection antigens and their recognition by cytotoxic T lymphocytes (CTLs). The authors highlight the notion of an immunosuppressive environment existing in tumors that reinforces CTL hyporesponsiveness. They suggest therapeutic vaccination, perhaps in conjunction with inhibitors of immunosuppression, could establish a local immunostimulatory milieu in the tumor that would facilitate activation of CTLs reactive to the vaccine antigen in addition to those CTLs that target other tumor antigens.
GeneTex offers an excellent selection of antibodies for the study of tumor immunology.
GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation. We are committed to the highest standards of product performance, and our scientists are dedicated to the goal of accelerating your discovery.
Visit
http://www.genetex.com for details.
Account Phone Number